Ariad Pharmaceuticals Inc.'s stock jumped after news of a victory valued at about $65.2 million in its patent lawsuit against Eli Lilly and Co. - though Lilly plans first to ask the judge to set aside the jury's verdict regarding Evista and Xigris and then to appeal, if necessary. (BioWorld Today)